[Effect of mildronate on life quality of patients with chronic heart failure].
OBJECTIVE
To study quality of life (QL) of patients with chronic heart failure (CHF) and QL changes resultant from mildronate therapy.


METHODS
QL was studied in 30 IHD patients with CHF of NYHA class II-IV, ejection fraction > 45%; 40 IHD patients without CHF and 30 healthy subjects. CHF patients were treated for 30 days with oral mildronate (250 mg 4 times a day). QL was assessed according to the method SF-36 Health Status Survey.


RESULTS
QL in CHF patients is much lower than that of the controls. Objective severity of the disease and subjective satisfaction with life do not always coincide. Mildronate in a dose 1 g/day per os may be beneficial for LQ of CHF patients.


CONCLUSIONS
It is thought desirable to include QL in analysis of efficiency of managing patients with CHF. SF-36 is a tool able to follow up changes in QL of CHF patients within a short-term treatment period.
Nedoshivin
A O
AO
Petrova
N N
NN
Kutuzova
A E
AE
Perepech
N B
NB
D000284:Administration, Oral; D000328:Adult; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D017060:Patient Satisfaction; D011788:Quality of Life; D013318:Stroke Volume / Q000187:drug effects; D016896:Treatment Outcome
D002317:Cardiovascular Agents; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate